BioNTech Announces Second Quarter 2023 Financial Results and ...

BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update ; Total revenues, 167.7, 3,196.5 ; Cost of sales, (162.9), (764.6) ; Research and ...

BioNTech Announces Second Quarter 2023 Financial Results

BioNTech Announces Second Quarter 2023 Financial Results and Corporate Update ; Total Revenues · 167.7, 3,196.5 ; Net Profit / (Loss), (190.4) ...

BioNTech Announces Second Quarter 2024 Financial Results and ...

BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update ; Retained earnings, 18,640.4 ; Other reserves, (1,038.2) ; Total ...

BioNTech Announces Second Quarter 2024 Financial Results

MAINZ, Germany, August 5, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for ...

BioNTech Announces Second Quarter Financial Results and ...

Second quarter revenues of €3.2 billion1, net profit of €1.7 billion and fully diluted earnings per share of €6.45 ($6.872) as well as first ...

BioNTech Reports Q2 2024 Financial Results and Corporate Update

For the second quarter of 2024, BioNTech reported revenues of €128.7 million, a decrease from €167.7 million in the same period in 2023. The ...

BioNTech Announces Fourth Quarter and Full Year 2023 Financial ...

“2023 was another year of good performance for BioNTech. We have maintained our leading position in the COVID-19 vaccine market which lays the ...

Pfizer Reports Second-Quarter 2023 Results

NEW YORK, Tuesday, August 1, 2023 – Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2023. The company narrowed its 2023 revenue ...

BioNTech to Report Second Quarter 2023 Financial Results and ...

MAINZ, Germany, July 24, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results ...

BioNTech Announces Third Quarter 2023 Financial Results and ...

For the nine months ended September 30, 2023, total revenues were €2,340.0 million2, compared to €13,032.3 million for the comparative prior ...

Moderna Reports Second Quarter 2024 Financial Results and ...

Net product sales for the second quarter of 2024 were $184 million, reflecting a 37% decrease compared to the same period in 2023. This ...

BioNTech Announces Third Quarter 2024 Financial Results and ...

Revenues reported were €1,244.8 million for the three months ended September 30, 2024, compared to €895.3 million for the comparative prior year ...

BioNTech Announces Second Quarter 2024 Financial... - Benzinga

BioNTech SE Reports Second Quarter 2024 Financial Results

Conclusion: BioNTech faced significant financial challenges in Q2 2024, primarily due to decreased COVID-19 vaccine revenue and increased R&D ...

Pfizer Reports Strong Second-Quarter 2024 Results And Raises ...

As an additional reference, see the '2024 Financial. Guidance' section of Pfizer's fourth-quarter 2023 earnings release. (7). References to ...

BioNTech Announces Fourth Quarter and Full Year 2021 Financial ...

“Driven by the continued global delivery of our COVID-19 vaccine, we are delighted to report a strong financial performance in both the fourth quarter and for ...

Financials - Pfizer Inc. - Investor Relations

Overview > Investor Relations > Financials > Quarterly Results. 2024. 2023 ... Quarterly Reports. Annual Reports. SEC Filings. End of Day Stock Quote. Events ...

BioNTech Announces Fourth Quarter and Full Year 2023 Financial ...

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update ; Total Revenues, 1,479.0, 4,278.3, 3,819.0, 17,310.6.

BioNTech : Announces Third Quarter 2024 Financial Results and ...

For the nine months ended September 30, 2024, loss per share was €3.83, compared to diluted earnings per share of €1.94 for the comparative ...

BioNTech Announces Third Quarter 2024 Financial Results and ...

BioNTech (BNTX) reported Q3 2024 financial results with revenues of €1.2 billion, net profit of €198.1 million, and diluted EPS of €0.81.